2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
33
Prostatic Neoplasms
32
Lymphoma, Large B-Cell, Diffuse
29
Lymphoma, Follicular
15
Leukemia
15
Lymphoma, Non-Hodgkin
13
Hodgkin Disease
11
Burkitt Lymphoma
10
Leukemia, Biphenotypic, Acute
8
Neoplasm Metastasis
7
Recurrence
6
Neoplasms
6
Lymphoma, Large-Cell, Anaplastic
6
Lymphoma, B-Cell
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Hemangioma
5
Ovarian Neoplasms
4
Multiple Myeloma
4
Immunoblastic Lymphadenopathy
4
Dendritic Cell Sarcoma, Interdigitating
4
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, B-Cell, Marginal Zone
3
Breast Neoplasms
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neurotoxicity Syndromes
2
Interventions
bicalutamide
5
enzalutamide
4
exemestane
2
darolutamide
2
abiraterone
2
pembrolizumab
1
ostarine
1
nilutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Prophylactic Mastectomy
1
Prednisolone
1
Panobinostat
1
Mifepristone
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Docetaxel
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bulbo-Spinal Atrophy, X-Linked
×
Prednisolone
×
Clear all
NCT06764485
2026-05-06
rechARge
Celgene
Phase 3
Recruiting
960 enrolled